MX2023011929A - Anticuerpos anti-c-met y conjugados de anticuerpo-farmaco. - Google Patents
Anticuerpos anti-c-met y conjugados de anticuerpo-farmaco.Info
- Publication number
- MX2023011929A MX2023011929A MX2023011929A MX2023011929A MX2023011929A MX 2023011929 A MX2023011929 A MX 2023011929A MX 2023011929 A MX2023011929 A MX 2023011929A MX 2023011929 A MX2023011929 A MX 2023011929A MX 2023011929 A MX2023011929 A MX 2023011929A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- drug conjugates
- antibodies
- antigen
- met antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21167423 | 2021-04-08 | ||
| PCT/EP2022/059059 WO2022214517A1 (en) | 2021-04-08 | 2022-04-06 | Anti-c-met antibodies and antibody-drug conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023011929A true MX2023011929A (es) | 2023-10-23 |
Family
ID=75438640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023011929A MX2023011929A (es) | 2021-04-08 | 2022-04-06 | Anticuerpos anti-c-met y conjugados de anticuerpo-farmaco. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240376214A1 (https=) |
| EP (1) | EP4320152A1 (https=) |
| JP (1) | JP2024515266A (https=) |
| KR (1) | KR20230166099A (https=) |
| CN (1) | CN117157325A (https=) |
| AU (1) | AU2022254291A1 (https=) |
| BR (1) | BR112023020801A2 (https=) |
| CA (1) | CA3214718A1 (https=) |
| CL (1) | CL2023002992A1 (https=) |
| IL (1) | IL306142A (https=) |
| MX (1) | MX2023011929A (https=) |
| WO (1) | WO2022214517A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024108193A2 (en) * | 2022-11-18 | 2024-05-23 | Epibiologics, Inc. | Degradation of cmet using a bispecific binding agent |
| WO2024131835A1 (en) * | 2022-12-20 | 2024-06-27 | Hansoh Bio Llc | Ligand-cytotoxicity drug conjugates and pharmaceutical uses thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2575402A1 (en) | 2004-08-05 | 2006-02-09 | Genentech, Inc. | Humanized anti-cmet antagonists |
| PA8849001A1 (es) | 2008-11-21 | 2010-06-28 | Lilly Co Eli | Anticuerpos de c-met |
| AR074439A1 (es) * | 2008-12-02 | 2011-01-19 | Pf Medicament | Anticuerpo anti-cmet (receptor c-met) |
| PT3056203T (pt) | 2010-04-21 | 2018-02-15 | Syntarga Bv | Conjugados de análogos de cc-1065 e ligantes bifuncionais |
| RU2608644C2 (ru) | 2010-11-03 | 2017-01-23 | арДЖЕН-ИКС Н.В. | Антитела против белка рецептора с-мет |
| US20140154251A1 (en) | 2011-10-05 | 2014-06-05 | Samsung Electronics Co., Ltd. | Anti c-met antibody and uses thereof |
| KR101463098B1 (ko) * | 2011-11-28 | 2014-11-27 | 한국생명공학연구원 | ｃ-Ｍｅｔ에 대한 인간항체에 약물이 접합된 약물 복합체 및 이의 용도 |
| KR102150616B1 (ko) * | 2013-09-12 | 2020-09-03 | 삼성전자주식회사 | c-Met 표적 화합물-생체활성 물질 접합체 및 그 용도 |
| SG11201609372UA (en) | 2014-05-22 | 2016-12-29 | Synthon Biopharmaceuticals Bv | Site-specific conjugation of linker drugs to antibodies and resulting adcs |
| ES2748295T3 (es) | 2014-09-16 | 2020-03-16 | Symphogen As | Anticuerpos anti-MET y composiciones |
| WO2016165580A1 (zh) * | 2015-04-17 | 2016-10-20 | 江苏恒瑞医药股份有限公司 | 抗c-Met抗体和抗c-Met抗体-细胞毒性药物偶联物及其医药用途 |
| PL3319597T3 (pl) * | 2015-07-10 | 2021-10-11 | Byondis B.V. | Kompozycje zawierające koniugaty przeciwciało-duokarmycyna |
| CA3026139C (en) | 2016-02-12 | 2023-09-12 | Synthon Biopharmaceuticals B.V. | Selective reduction of cysteine-engineered antibodies |
| SI3626273T1 (sl) | 2016-05-17 | 2021-04-30 | Abbvie Biotherapeutics Inc. | Konjugati protitelesa proti CMET in zdravila ter postopki za njihovo uporabo |
| GB201611123D0 (en) | 2016-06-27 | 2016-08-10 | Euremab Srl | Anti met antibodiesand uses thereof |
| HUE054571T2 (hu) * | 2016-09-14 | 2021-09-28 | Merck Patent Gmbh | Hatékony tumorgátlásra szolgáló C-MET elleni ellenanyagok és ellenanyag-drog konjugátumaik |
| US11419944B2 (en) | 2016-10-11 | 2022-08-23 | Byondis B.V. | Non-linear self-immolative linkers and conjugates thereof |
| TWI782930B (zh) * | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| HRP20210922T1 (hr) * | 2016-11-23 | 2021-09-03 | Eli Lilly And Company | Konjugati protutijela protiv met s lijekom |
| US20180230218A1 (en) * | 2017-01-04 | 2018-08-16 | Immunogen, Inc. | Met antibodies and immunoconjugates and uses thereof |
| US11696958B2 (en) | 2017-05-23 | 2023-07-11 | Byondis B.V. | Dual conjugation process for preparing antibody-drug conjugates |
| JP7325339B2 (ja) * | 2017-05-30 | 2023-08-14 | チョン クン ダン ファーマシューティカル コーポレーション | 新規な抗ｃ－Ｍｅｔ抗体およびその用途 |
| EP3774923A4 (en) * | 2018-03-28 | 2021-12-29 | Mitsubishi Tanabe Pharma Corporation | Drug conjugates of cmet monoclonal binding agents, and uses thereof |
-
2022
- 2022-04-06 BR BR112023020801A patent/BR112023020801A2/pt unknown
- 2022-04-06 JP JP2023561850A patent/JP2024515266A/ja active Pending
- 2022-04-06 MX MX2023011929A patent/MX2023011929A/es unknown
- 2022-04-06 WO PCT/EP2022/059059 patent/WO2022214517A1/en not_active Ceased
- 2022-04-06 EP EP22714223.9A patent/EP4320152A1/en active Pending
- 2022-04-06 US US18/554,339 patent/US20240376214A1/en active Pending
- 2022-04-06 CN CN202280026738.8A patent/CN117157325A/zh active Pending
- 2022-04-06 KR KR1020237036317A patent/KR20230166099A/ko active Pending
- 2022-04-06 IL IL306142A patent/IL306142A/en unknown
- 2022-04-06 AU AU2022254291A patent/AU2022254291A1/en active Pending
- 2022-04-06 CA CA3214718A patent/CA3214718A1/en active Pending
-
2023
- 2023-10-05 CL CL2023002992A patent/CL2023002992A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL306142A (en) | 2023-11-01 |
| BR112023020801A2 (pt) | 2023-12-12 |
| WO2022214517A1 (en) | 2022-10-13 |
| CA3214718A1 (en) | 2022-10-13 |
| CL2023002992A1 (es) | 2024-04-19 |
| AU2022254291A1 (en) | 2023-10-12 |
| KR20230166099A (ko) | 2023-12-06 |
| AU2022254291A9 (en) | 2024-02-22 |
| CN117157325A (zh) | 2023-12-01 |
| EP4320152A1 (en) | 2024-02-14 |
| JP2024515266A (ja) | 2024-04-08 |
| US20240376214A1 (en) | 2024-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022007924A2 (es) | Conjugados de anticuerpo y fármaco de eribulina anti-mesotelina y métodos de uso | |
| AR122546A1 (es) | Conjugados de anticuerpo anti bcma-fármaco y métodos de uso | |
| MX2020007077A (es) | Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados. | |
| CL2025001913A1 (es) | Anticuerpo anti-nectina-4; conjugado que lo comprende; composición farmacéutica; y su uso. | |
| CL2023002992A1 (es) | Anticuerpos anti-c-met y conjugados de anticuerpo-fármaco | |
| ECSP21044421A (es) | Anticuerpos anti-pmel17 y conjugados de los mismos | |
| MX2023012848A (es) | Conjugados de anticuerpo-farmaco anti-c-met. | |
| ECSP20020949A (es) | Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos | |
| CO2025002301A2 (es) | Anticuerpos anti-ccr8 y métodos de uso | |
| MX2020010110A (es) | Conjugados de farmacos de agentes de union monoclonales de cmet, y usos de los mismos. | |
| CL2025001502A1 (es) | Conjugados anticuerpo-fármaco anti-cea y métodos de uso | |
| CL2025001398A1 (es) | Anticuerpos anti-cd48, conjugados de anticuerpo-fármaco, y usos de los mismos | |
| CL2023003905A1 (es) | Conjugados novedosos que comprenden fosfoantígenos y su uso terapéutico | |
| CL2023003209A1 (es) | Composición farmacéutica de pembrolizumab y su uso | |
| AR129382A1 (es) | Conjugados de anticuerpo-fármaco inhibidores de bcl-xl y met y sus métodos de uso | |
| MX2023014683A (es) | Conjugados de anticuerpo anti-egfrviii y farmaco y usos de los mismos. | |
| CO2025013396A2 (es) | Anticuerpos muc1 y cd16a y métodos de uso | |
| BR112019002213A2 (pt) | composições e o uso das mesmas para tratar ou prevenir rosácea | |
| AR134425A1 (es) | Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos | |
| DOP2025000322A (es) | Anticuerpos de nectina-4 y conjugados anticuerpo-fármaco | |
| PY24103486A (es) | Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos | |
| CL2025002693A1 (es) | Anticuerpos multiespecíficos anti-cd3 y métodos de uso. | |
| CL2025002685A1 (es) | Anticuerpos multiespecíficos anti-cldn6 y anti-cd3 y métodos de uso. | |
| MX2025010218A (es) | Anticuerpos multiespecificos anti-cldn6 y anti-cd3 y metodos de uso | |
| MX2022008745A (es) | Anticuerpos anti-nkp30 y metodos de uso. |